Regeneron Pharmaceuticals is set to acquire 23andMe for $256 million following its bankruptcy filing due to declining demand ...

Investors burned by President Trump’s trade fight now have to contend with a spending megabill that risks swelling the ...

The Moody’s announcement sent the yield on a 30-year Treasury bond to a high of 5.01% at one point on Monday. Bond yields ...

The latest warnings from JPMorgan’s Jamie Dimon on geopolitical risks and tariffs have become par for the course.While he ...

Home Depot doesn’t expect to raise prices because of tariffs, saying it has spent years diversifying the sources for the ...

The Dow Jones Industrial Average finished up 0.3 per cent at 42,792.07. Read more at straitstimes.com. Read more at ...

On May 8, 2025, the Boston Bar Association hosted its annual White Collar Crime Conference, a reoccurring theme of which was ...

Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, ...

The US’s credit rating took a hit on Friday, after Moody’s downgraded the country’s AAA rating. And then yesterday, bond prices followed suit. Here to explain the significance of these market moves is ...

Mufg Securities Americas Inc. made a modest splash in the biotech pool, acquiring 1,554 shares of Regeneron Pharmaceuticals ...

Regeneron Pharmaceuticals on Monday said it would buy genetic testing company 23andMe, which filed for bankruptcy in March ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies insisted the sensitive genetic data provided to 23andMe by 15 million ...